Literature DB >> 29344971

Clear cell carcinomas of the ovary and kidney: clarity through genomics.

Jennifer X Ji1, Yi Kan Wang2, Dawn R Cochrane2, David G Huntsman1,2.   

Abstract

Clear cell ovarian carcinoma (CCOC) and clear cell renal cell carcinoma (ccRCC) both feature clear cytoplasm, owing to the accumulation of cytoplasmic glycogen. Genomic studies have demonstrated several mutational similarities between these two diseases, including frequent alterations in the chromatin remodelling SWI-SNF and cellular proliferation phosphoinositide 3-kinase-mammalian target of rapamycin pathways, as well as a shared hypoxia-like mRNA expression signature. Although many targeted treatment options have been approved for advanced-stage ccRCC, CCOC patients are still treated with conventional platinum and taxane chemotherapy, to which they are resistant. To determine the extent of similarity between these malignancies, we performed unsupervised clustering of mRNA expression data from these cancers. This review highlights the similarities and differences between these two clear cell carcinomas to facilitate knowledge translation within future research efforts.
Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  clear cell ovarian carcinoma; clear cell renal cell carcinoma; genomic; metabolism

Mesh:

Substances:

Year:  2018        PMID: 29344971     DOI: 10.1002/path.5037

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  13 in total

1.  The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer.

Authors:  Artur A Serebrenik; Prokopios P Argyris; Matthew C Jarvis; William L Brown; Martina Bazzaro; Rachel I Vogel; Britt K Erickson; Sun-Hee Lee; Krista M Goergen; Matthew J Maurer; Ethan P Heinzen; Ann L Oberg; Yajue Huang; Xiaonan Hou; S John Weroha; Scott H Kaufmann; Reuben S Harris
Journal:  Clin Cancer Res       Date:  2020-02-14       Impact factor: 12.531

2.  Bilateral Primary Ovarian Clear Cell Carcinoma in an Iranian Woman: a Case Report.

Authors:  Fatemeh Samiee-Rad; Mahdi Ghaebi; Arezoo Bajelan
Journal:  Indian J Surg Oncol       Date:  2020-10-01

3.  SR-B1 and CD10 combined immunoprofile for differential diagnosis of metastatic clear cell renal cell carcinoma and clear cell carcinoma of the ovary.

Authors:  Teng Jiang; Xiaoli Diao; Meili Ding; Xiao Niu; Chao Wang; Yan Qi; Wei Jia; Lijuan Pang; Wenhao Hu; Hong Zou; Feng Li
Journal:  J Mol Histol       Date:  2021-02-19       Impact factor: 2.611

4.  DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.

Authors:  Kelly L Bolton; Francesmary Modugno; Ellen L Goode; Julie M Cunningham; Stacey J Winham; Chen Wang; Britta Weiglt; Zhuxuan Fu; Sebastian M Armasu; Bryan M McCauley; Alison H Brand; Yoke-Eng Chiew; Esther Elishaev; Charlie Gourley; Catherine J Kennedy; Angela Laslavic; Jenny Lester; Anna Piskorz; Magdalena Sekowska; James D Brenton; Michael Churchman; Anna DeFazio; Ronny Drapkin; Kevin M Elias; David G Huntsman; Beth Y Karlan; Martin Köbel; Jason Konner; Kate Lawrenson; Elli Papaemmanuil
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-10-25       Impact factor: 4.090

5.  Fairly rare clear cell adenocarcinoma mimicking liver cancer: a case report.

Authors:  Norifumi Harimoto; Kei Hagiwara; Takahiro Yamanaka; Norihiro Ishii; Takamichi Igarashi; Akira Watanabe; Norio Kubo; Kenichirou Araki; Hayato Ikota; Masafumi Suyama; Takeshi Maki; Shinichi Aishima; Hiroyuki Kuwano; Ken Shirabe
Journal:  Surg Case Rep       Date:  2018-08-16

6.  Identification of Candidate Genes Associated with Susceptibility to Ovarian Clear Cell Adenocarcinoma Using cis-eQTL Analysis.

Authors:  Jihye Kim; Joon-Yong Chung; Jae Ryoung Hwang; Yoo-Young Lee; Tae-Joong Kim; Jeong-Won Lee; Byoung-Gie Kim; Duk-Soo Bae; Chel Hun Choi; Stephen M Hewitt
Journal:  J Clin Med       Date:  2020-04-16       Impact factor: 4.241

7.  A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis.

Authors:  Yilong Zou; Michael J Palte; Amy A Deik; Haoxin Li; John K Eaton; Wenyu Wang; Yuen-Yi Tseng; Rebecca Deasy; Maria Kost-Alimova; Vlado Dančík; Elizaveta S Leshchiner; Vasanthi S Viswanathan; Sabina Signoretti; Toni K Choueiri; Jesse S Boehm; Bridget K Wagner; John G Doench; Clary B Clish; Paul A Clemons; Stuart L Schreiber
Journal:  Nat Commun       Date:  2019-04-08       Impact factor: 14.919

8.  Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE-100.

Authors:  Shin Nishio; Koji Matsumoto; Kazuhiro Takehara; Naoki Kawamura; Kosei Hasegawa; Nobuhiro Takeshima; Daisuke Aoki; Shoji Kamiura; Atsushi Arakawa; Eiji Kondo; Tomoko Hirakawa; Keiko Yamamoto; Masayuki Aoki; Karen Stein; Stephen Keefe; Keiichi Fujiwara; Kimio Ushijima
Journal:  Cancer Sci       Date:  2020-02-28       Impact factor: 6.716

Review 9.  Tumor Profiling at the Service of Cancer Therapy.

Authors:  Ceres Fernandez-Rozadilla; Ana Rita Simões; Matilde E Lleonart; Amancio Carnero; Ángel Carracedo
Journal:  Front Oncol       Date:  2021-01-11       Impact factor: 6.244

10.  The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.

Authors:  Hao Wang; Lei Fang; Jing Jiang; Ye Kuang; Beidi Wang; Xiumin Shang; Peilin Han; Yue Li; Meimei Liu; Zongfeng Zhang; Peiling Li
Journal:  Cell Death Dis       Date:  2018-10-30       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.